{"created":"2023-05-15T09:08:42.386463+00:00","id":16365,"links":{},"metadata":{"_buckets":{"deposit":"47792c03-bcba-48f5-b079-f0e67f343771"},"_deposit":{"created_by":14,"id":"16365","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"16365"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00016365","sets":["1875:1885:2169"]},"author_link":["32237","32238","32239"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-09-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"20","bibliographicPageStart":"16","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"市立室蘭総合病院医誌 = Journal of Muroran City General Hospital"},{"bibliographic_title":" Journal of Muroran City General Hospital","bibliographic_titleLang":"en"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"新規抗アンドロゲン薬であるアビラテロン（ザイティガ）の去勢抵抗性前立腺癌に対する治療成績について検討した。対象は2014 年9月から2018 年5月までの間に当院でアビラテロンを開始した23 例で、評価項目は前立腺特異抗原（prostate specific antigen：PSA）変化率、全生存率（overall survival：OS）、無増悪生存率（progression-free survival：PFS）、有害事象（adverse events：AEs）とした。また、OS、PFS をドセタキセル使用前後およびエンザルタミド使用前後に層別化し検討した。PSA 奏効が得られたのは23 例中7例であった。OS 中央値は20.1 か月で、ドセタキセル使用前は20.1 か月、使用後は10.6 か月、エンザルタミド使用前では34.0 か月、使用後は20.1 か月でいずれも有意差は認めなかった。PFS 中央値は1.8 か月で、ドセタキセル使用前は3.5 月、使用後は1.4 か月で、エンザルタミド使用前は4.4 か月、使用後は1.3 か月でいずれも有意差を認めた。AEs は6症例に見られ、2例でアビラテロン中止となった。当科の治療成績は、これまでの報告に比して劣るが、背景因子の違いや、早期中止例が多かったことが原因と考えられた。適切な症例選択と使用方法により治療効果が得られると考えられた。","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立室蘭総合病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0289-2774","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"野藤, 誓亮"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"加藤, 隆一"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"酒井, 康之"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-10-15"}],"displaytype":"detail","filename":"n028927744416.pdf","filesize":[{"value":"1.6 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"n028927744416","url":"https://sapmed.repo.nii.ac.jp/record/16365/files/n028927744416.pdf"},"version_id":"ccbbcaae-2f2d-476e-b4b7-fce40a564242"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"去勢抵抗性前立腺癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"ホルモン療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"新規抗アンドロゲン薬","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"アビラテロン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"当院における去勢抵抗性前立腺癌に対するアビラテロンの治療成績","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"当院における去勢抵抗性前立腺癌に対するアビラテロンの治療成績","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["2169"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-10-15"},"publish_date":"2019-10-15","publish_status":"0","recid":"16365","relation_version_is_last":true,"title":["当院における去勢抵抗性前立腺癌に対するアビラテロンの治療成績"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T03:08:44.431353+00:00"}